This site is intended only for healthcare professionals in UAE, Kuwait, Qatar, Bahrain, Oman.

Search

Menu

Close

Sign In or Register

Log OutOur Medicines Therapy AreasExplore ContentExplore Content

Events

Downloadable materialsVideosLet's ConnectLet's ConnectContact usPfizer medical information

Menu

Close

AboutAboutCOVID OverviewIndicationsMechanism of ActionEfficacyDosingSafetyPatient ProfilesFAQsImportant Safety InformationResourcesResourcesEventsMaterialsVideos

This information is only valid for healthcare professionals in Bahrain, Kuwait, Qatar & UAE.
PaxlovidTM (nirmatrelvir and ritonavir) is available, marketed and has a Health Registry only in Bahrain, Kuwait, Qatar & UAE.

Information on how to access PaxlovidTM (nirmatrelvir and ritonavir) prescribing information and adverse event reporting can be found at the bottom of the page.

Important Safety Information1Therapeutic indications

Paxlovid is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.

Contraindications

Paxlovid is contraindicated in patients:
- with a history of clinically significant hypersensitivity to the active substances (nirmatrelvir/ritonavir) or to any of the excipients
- with severe hepatic impairment.
- with severe renal impairment.

Dosage and administration 

The recommended dosage is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) all taken together orally twice daily for 5 days. Paxlovid should be given as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 5 days of onset of symptoms.

Special warnings and precautions for use

Patients show risk of serious adverse reactions due to interactions with other medicinal products. Hepatic transaminase elevations, clinical hepatitis and jaundice have occurred in patients receiving ritonavir. there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection. Nirmatrelvir tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Paxlovid is not recommended during pregnancy and in women of childbearing potential not using effective contraception.

The adverse reactions include very common (≥ 1/10) include Nervous system and Gastrointestinal disorders .
Patient Profiles
 Learn More Loading
Mechanism of Action
 Learn More Loading
Efficacy Learn  MoreLoading


Reference: 1. PaxlovidTM (nirmatrelvir and ritonavir) Local Product Document. Revision Date: October 2022 for Kuwait, January 2024 for Bahrain, Qatar & UAE.
COVID-19 Overview

SARS-CoV-2 replicates quickly2-4

 Learn MoreLoading Indication

PAXLOVID™: Indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-191

 Learn More Loading Dosing

PAXLOVID™: Taken orally, at home, twice daily for 5 days1

 Learn More Loading Mechanism of Action

Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease.1

 Learn More Loading Efficacy

PAXLOVID™ significantly reduces the risk of hospitalisation or death5

 Learn More Loading Safety Profile

PAXLOVID™ is a well-tolerated drug, as per the EPIC-HR trial5

 Learn More Loading

Prescribing Information:
 

Bahrain Prescribing Information
Kuwait Prescribing Information
Qatar Prescribing Information
UAE Prescribing Information
PP-C1D-BHR-0061

This information is valid only for healthcare professionals in Bahrain, Kuwait, Qatar & UAE.

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign In or Register

AccountSign Out

Copyright © 2025 Pfizer Gulf FZ LLC. All rights reserved.

 

i- The product information provided in this site is intended only for Healthcare Professionals of UAE, Kuwait, Qatar, Bahrain, Oman.

 

ii- The information contained on this website is offered for educational purposes only and does not represent medical advice, diagnosis, treatment or a professional recommendation. Pfizer will not be responsible for the use or interpretation of the information by the user of the website.

 

iii- The products discussed herein may have a different product labeling than authorized in your country and may not be available in some territories.

PP-UNP-BHR-0411

You are now leaving Pfizer

You are now leaving Pfizerpro and will be directed to our provider to complete your registration. Any personal information that you may find pre-populated from your Pfizerpro profile, or you may provide, will be governed by our Privacy Policy. Your data will not be used for any other purpose.

 

You are now leaving PfizerPro
​
You are leaving the Pfizer Portal - would you like to continue?
 

​​​​​​​